Stockwinners Market Radar for August 11, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

16:32 EDT Nuvve Holding, Blue Bird expand partnership for electric school buses - Nuvve Holding (NVVE) and Blue Bird (BLBD) plan to deploy the extensive financing capabilities from Levo Mobility, Nuvve's recently formed joint venture with Stonepeak Partners, across Blue Bird's distribution network, allowing customers to lease V2G electric school buses, related charging infrastructure, and energy management for a flat monthly fee with no upfront costs. The Nuvve and Blue Bird partnership expansion also makes V2G ubiquitous in the electric school bus market by integrating Nuvve V2G charging infrastructure within the Blue Bird manufacturing and distribution network. Levo will offer its Fleet-as-a-Service model through Blue Bird's nationwide distribution network, providing fully financed electric school buses along with associated charging infrastructure, service, and energy management to qualified Blue Bird customers and dealers. Levo has a capital commitment of up to $750M with the potential to electrify up to 3,500 school buses. The two companies also plan to deploy Nuvve V2G charging stations along with electric buses at select Blue Bird dealers in multiple states across the U.S.

16:29 EDT Rexford Industrial acquires three industrial properties for $115.2M - Rexford Industrial acquired three industrial properties comprised of a 5.8 acre redevelopment site, a 107,023 SF industrial building and a 22.3 acre industrial outdoor storage site for an aggregate purchase price of $115.2M. The acquisitions were funded using cash on hand. In July and August, the company acquired these properties: 1901 Via Burton, located in Fullerton, within the Orange County-North submarket for $24.2M or $96 per land square foot. The company intends to re-develop the current 5.8 acre site into a new 139,000 square foot warehouse. The stabilized unlevered cash yield on total investment is projected to be approximately 5.5% upon lease-up. 1555 S. Cucamonga Ave, located in Ontario, CA, for $21.0M or $51 per land square foot. The 100% leased, 107,023 SF multi-building industrial property is located near the Ontario Airport. The company intends to redevelop the site with a new 213,000 square foot modern, Class A logistics building. 1800 E. Lomita Blvd, located within the LA - South Bay submarket for $70.0M or $73 per land square foot. The site is zoned for by-right outdoor container storage and stacking. The investment generates an initial 3.6% unlevered yield which is expected to grow substantially over time as current in-place leases at rental rates estimated to be nearly 50% below market are rolled to higher market rents.

16:24 EDT Target names David Abney, Gail Boudreaux to board of directors - Target (TGT) announced its board of directors elected David Abney, former chairman of the board and CEO of United Parcel Service (UPS), and Gail Boudreaux, president and CEO of Anthem (ANTM) as directors. Abney's appointment is effective immediately and Boudreaux's appointment becomes effective September 23.

16:23 EDT Atreca reports cash, equivalents of $182.3M at June 30

16:22 EDT Aileron Therapeutics sees cash, equivalents funding operations into 2H23 - Cash, cash equivalents and investments on June 30, 2021 were $59.5M, compared to $13.8M at December 31, 2020. The company expects, based on its current operating plan, that its existing cash, cash equivalents and investments will fund operations into the second half of 2023.

16:22 EDT Vine Energy cancels Q2 conference call - Vine Energy (VEI) announced that it cancelled its second-quarter 2021 conference call scheduled for August 16, 2021 at 9am Central time following the announcement of the definitive agreement in which Chesapeake Energy (CHK) intends to acquire Vine. The call is not expected to be rescheduled. The company expects to file its second-quarter 2021 results on Form 10-Q on or before August 16, 2021.

16:20 EDT Royal Gold sees Q1 stream segment sales 62K-67K GEOs - For the quarter ended September 30, 2021, Royal Gold expects stream segment sales to range between 62,000 and 67,000 GEOs with quarter-end inventory ranging between 22,000 and 27,000 GEOs. For the 6-month stub period ended December 31, 2021, Royal Gold expects total stream segment and royalty sales volume to range between 175,000 and 185,000 GEOs4. For the same period, depreciation, depletion and amortization expense is expected to range between $520 and $570 per GEO. Other than potential remaining conditional funding at the Khoemacau Project and potential exploration and resource payments under the NX Gold Mine stream, Royal Gold has no other project capital commitments or financing obligations. 4 Commodity price assumptions for GEO projections include: $1,750 per ounce of gold, $25.50 per ounce of silver, $4.15 per pound of copper, $8.00 per pound of nickel, $0.95 per pound of lead, and $1.25 per pound of zinc.

16:19 EDT Agree Realty announces resignation of CFO Simon Leopold - Agree Realty announced that Simon Leopold has resigned from his positions as Executive Vice President, CFO and Secretary of the company effective immediately. The Board of Directors also announced that it will commence a formal search, which will consider internal and external candidates, for a new CFO. Peter Coughenour, current Vice President, Corporate Finance who joined the company in 2015, has been appointed to the position of interim CFO until a permanent replacement is identified. David Wolff, the company's Chief Accounting Officer, will continue to lead the day-to-day operations of the company's accounting department.

16:18 EDT ExOne trading halted, news pending

16:15 EDT Histogen provides update on upcoming milestones - HST 003 - The company anticipates having top-line results from Phase 1/2 clinical study of HST 003 in the second quarter of 2022. HST 004 - The company anticipates filing an IND for HST 004 in the second quarter of 2022. Emricasan - Along with partner Amerimmune, are currently evaluating our clinical development plans for the emricasan program and expect to complete our evaluation in the third quarter of 2021.

16:14 EDT Apogee Enterprises announces restructuring and cost cutting plans - Apogee Enterprises announced plans to realign and simplify its business structure to "bring a stronger focus to serving customers, enable a more competitive cost model, and better position the company for future growth and improved profitability." The company will begin executing these actions immediately and expects to be substantially completed in the first quarter of fiscal 2023. When completed, the restructuring actions announced are expected to reduce the company's workforce by approximately 400 employees. These actions build on the company's previously announced restructuring and cost savings initiatives. In October 2020, the company announced that it had identified opportunities for $10M-$20M of annualized cost savings, to be achieved by the end of fiscal 2023. With today's announcement, the company now expects to achieve $20M-$30M of annualized savings by the end of fiscal 2023. The company expects pre-tax charges between $30M-$35M related to today's announcement, primarily for asset impairments and severance. The company will record these charges as they are incurred and anticipates the majority will be recorded in the second quarter of fiscal 2022. Excluding these expected charges, the company is maintaining its previous guidance for fiscal 2022 of adjusted earnings between $2.20 to $2.40 per diluted share.

16:12 EDT Accuray CFO Shig Hamamatsu stepping down September 3 - Accuray's CFO Shig Hamamatsu announced his resignation from the company to pursue an opportunity in another industry. Hamamatsu will continue as CFO through September 3 to help ensure a smooth transition. The company has appointed Brandy Green, VP, Corporate Controller, as Interim CFO effective September 4, and has initiated a national search to identify a permanent replacement.

16:11 EDT Vroom sees triple digit y/y growth in ecommerce unit sales for FY21 - The company said: "For the full year 2021, we continue to expect triple digit year-over-year growth in ecommerce unit sales and more than 200% year-over-year growth in aggregate gross profit."

16:07 EDT Royal Gold acquires royalty on Red Chris Mine for $165M - Royal Gold announced that its wholly owned subsidiary, International Royalty Corporation, has acquired a 1.0% Net Smelter Return Royalty covering the currently known mineralization and prospective exploration areas that constitute a portion of the Red Chris Mine in British Columbia, Canada. Royal Gold paid $165M in cash consideration for the Royalty to Glencore Canada Corporation, a wholly owned subsidiary of Glencore International AG. Red Chris is owned and operated by a joint venture, which is owned 70% by Newcrest Mining Ltd. and 30% by Imperial Metals Corporation, in which Newcrest is the operator.

16:06 EDT Lordstown Motors sees FY21 capital expenditures $375M-$400M - The company expects FY21 Endurance production to be limited to coincide with commercialization roadmap. Sees FY21 operating expenses $95M-$105M.

16:06 EDT American Public Education to acquire Graduate School USA for $1M - American Public Education has signed an agreement to acquire substantially all the assets of Graduate School USA, providers of training to the federal government. Established in 1921 as part of the U.S. Department of Agriculture, GSUSA provides training to the federal workforce through a catalog of over 300 courses specializing in foundational and continuing professional development, as well as leadership training to advance the performance of government agencies through the competency and career advancement of their employees. With the onset of the pandemic, GSUSA accelerated its shift to online learning and has been delivering courses in a virtual modality as well. APEI is acquiring substantially all of GSUSA's assets for a purchase price of $1M and GSUSA will be a new stand-alone subsidiary of APEI. Over the past three fiscal years, GSUSA has generated over $20M in average annual revenue. The transaction is anticipated to close some time during 4Q21. APEI does not expect any material impact to its operating income in 2021 related to GSUSA.

16:02 EDT Insulet introduces Omnipod Dash system at Australasian Diabetes Congress - Insulet presented the Omnipod DASH Insulin Management System to healthcare providers attending the virtual Australasian Diabetes Congress. Insulet expects to begin taking customer orders for Omnipod DASH by the end of August.

16:00 EDT Equillium announces update to EQUALISE study - Equillium announced additional data from the EQUALISE Type A portion of the study in systemic lupus erythematosus patients. The exploratory data set shows that patients without a diagnosis of lupus nephritis but with elevated urine protein/creatine ratio (UPCR) greater than200 mg/g experienced a mean decrease from baseline in UPCR of 33% and 42% at Days 29 and 57 respectively, following subcutaneous doses of itolizumab on Days 1 and 15. Notably, one subject who had baseline UPCR of 1,505 mg/g declined to 974 mg/g at Day 29 and 857 mg/g by Day 57. Additionally, patients with elevated albumin/creatinine ratio experienced a mean decrease from baseline in ACR of 22% and 53% at Days 29 and 57 respectively. "We are intrigued by this observation from our Type A portion of the study in SLE patients who did not have a diagnosis of lupus nephritis and entered the study with elevated proteinuria, and experienced reductions in UPCR and ACR following two doses of itolizumab," said Dolca Thomas, executive vice president of research and development and chief medical officer of Equillium. "There is ongoing research in the field of rheumatology and nephrology that suggests patients who have elevated proteinuria with UPCR greater than 200 mg/g or ACR greater that 30 mg/g, which is below the typical diagnostic threshold for LN and other kidney diseases, may have subclinical disease - sometimes referred to as silent LN - where early intervention with a safe and active therapy may prevent more severe outcomes. We are continuing to analyze this exploratory data and look forward to initial results from active LN patients in the Type B portion of the EQUALISE study that is now enrolling."

15:52 EDT Soaring Eagle, Ginkgo Bioworks announce effectiveness of registration statement - Ginkgo Bioworks and Soaring Eagle Acquisition Corp. (SRNG) announced that the Securities and Exchange Commission has declared effective the registration statement on Form S-4 filed by Soaring Eagle with the SEC relating to the previously announced business combination between Ginkgo and Soaring Eagle. Ginkgo and Soaring Eagle expect to close the transaction in the third quarter, at which point Ginkgo's Class A common stock will be listed on the New York Stock Exchange under the ticker symbol "DNA". The business combination is expected to provide up to $2.5B of gross cash proceeds, including Soaring Eagle's $1.725B of cash in trust, subject to any redemptions by Soaring Eagle shareholders, and $775M in gross proceeds from a PIPE transaction priced at $10.00 per share of Class A common stock of Soaring Eagle to be funded immediately prior to the closing of the transaction.

14:54 EDT AMN Healthcare director Harris sells 15,000 common shares - In a regulatory filing, AMN Healthcare director R. Jeffrey Harris disclosed the sale of 15,000 common shares of the company on August 9 at a price of $105.0511 per share.

14:26 EDT Invitae CEO says consolidation to be 'name of the game for the next decade' - Speaking at the UBS Genomics 2.0 & MedTech Innovations Summit, Invitae (NVTA) CEO Sean George said that it could "not comment" on Bloomberg's report saying that Exact Sciences had approached the company about a potential tie-up. Nonetheless, the executive added that, "what I can say is the industry is going to tighten up really quick. Consolidation is going to be the name of the game for the next decade."

13:55 EDT North American rail traffic rose 1.1% in week ended August 7 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending August 7. For this week, total U.S. weekly rail traffic was 509,607 carloads and intermodal units, up 2.4% compared with the same week last year.Total carloads for the week ending August 7 were 234,336 carloads, up 6.3% compared with the same week in 2020, while U.S. weekly intermodal volume was 275,271 containers and trailers, down 0.6% compared to 2020. For some rail traffic categories, percentage changes for the current week compared with the same week in 2020 are inflated because of the widespread shutdowns - and subsequent large reduction in rail volumes - that impacted many economic sectors last year at this time...North American rail volume for the week ending August 7 on 12 reporting U.S., Canadian and Mexican railroads totaled 325,978 carloads, up 4.1% compared with the same week last year, and 358,442 intermodal units, down 1.5% compared with last year. Total combined weekly rail traffic in North America was 684,420 carloads and intermodal units, up 1.1%. North American rail volume for the first 31 weeks of 2021 was 21,562,185 carloads and intermodal units, up 10.7% compared with 2020. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP), Trinity Industries (TRN), Greenbrier, GBX) and FreightCar America (RAIL). Reference Link

12:53 EDT W.R. Grace, Chevron joint venture announces award of FCM agreement from Bapco - Advanced Refining Technologies, or "ART," the joint venture of W. R. Grace (GRA) and Chevron (CVX), announced the award of an FCM agreement by state-owned Bahrain Petroleum Company, or "Bapco." The exclusive, 5-year agreement, which includes an option to renew for an additional five years, is valued at $240M and is "the largest catalyst management agreement ever signed in Bapco's history," the companies said. "As part of the BMP, Bapco will boost Bahrain's oil refinery processing capacity from 267,000 b/d to 380,000 b/d. In addition, ART will supply its Resid Hydrocracking catalyst technology for a wide variety of feedstocks to maximize bottom of the barrel upgrading. The technology is the industry-leading catalyst for metals capacity and sediment control. In addition, ART will provide FCM services for the reclamation of metals from spent catalysts," the companies said.

12:42 EDT Endo's Par Pharmaceutical granted approval for ANDA for generic Chantix - According to the FDA website, an ANDA from Par Pharmaceutical, an Endo International (ENDP) company, for Varenicline Tablets, 0.5 mg and 1 mg, was granted approval on August 11. The generic is a version of Pfizer's (PFE) brand name drug Chantix, which is indicated for use as an aid to smoking cessation treatment. Reference Link

12:30 EDT Eliem Therapeutics Inc trading halted, volatility trading pause

12:01 EDT Virgin Galactic falls -15.4% - Virgin Galactic is down -15.4%, or -$4.83 to $26.50.

12:00 EDT On24 falls -28.4% - On24 is down -28.4%, or -$9.19 to $23.12.

12:00 EDT Doximity rises 17.9% - Doximity is up 17.9%, or $9.45 to $62.38.

11:57 EDT Stable Road Acquisition stockholders approve Momentus combination - Stable Road Acquisition announced that stockholders of Stable Road approved the proposed business combination with Momentus at the special meeting of stockholders held on August 11, 2021. The combined company will retain the Momentus name and its securities are expected to begin trading on the NASDAQ Global Select Market under the new symbol "MNTS" for Momentus stock and "MNTSW" for Momentus warrants on August 13, 2021, following the close of the business combination, which is expected to take place on August 12, 2021. Over 97% of the votes cast at the meeting voted to approve the business combination. Holders of approximately 55% percent of Stable Road's issued and outstanding shares cast votes at the Special Meeting. Stable Road also announced that an aggregate of approximately 3.5N shares of Stable Road's Class A common stock were submitted for redemption by public stockholders in connection with the vote, representing approximately 20% of all issued and outstanding shares of Class A common stock. After giving effect to the redemptions, approximately $137M will be disbursed from Stable Road's trust account to Momentus upon the closing of the business combination which, when combined with the $110M equity PIPE expected to be consummated concurrently with the closing, will provide Momentus with approximately $247M in total available cash, before transaction fees, expenses and payments related to the previously announced repurchase of its co-founders' shares.

11:47 EDT Oversight Board overturns Facebook's removal of post criticizing Myanmar coup - The Facebook Oversight Board has overturned Facebook's decision to remove a post in Burmese under its Hate Speech Community Standard. The Board found that the post did not target Chinese people, but the Chinese state. Specifically, it used profanity to reference Chinese governmental policy in Hong Kong as part of a political discussion on the Chinese government's role in Myanmar. The decision requires the post to be restored. In a policy advisory statement, the Board recommends that Facebook: Ensure that its Internal Implementation Standards are available in the language in which content moderators review content. If necessary to prioritize, Facebook should focus first on contexts where the risks to human rights are more severe, the board said. Reference Link

11:11 EDT Carvana banned from selling vehicles in Raleigh area for 180 days - Carvana has been banned from selling vehicles in the Raleigh, North Carolina area until January 29, 2022 as part of a settlement agreement with the North Carolina Division of Motor Vehicles, a court said in a filing. According to North Carolina officials, Carvana failed to deliver titles to the DMV and perform state inspections. Reference Link

10:27 EDT GigaGen doses first patient in Phase 1 trial for GIGA-2050 - GigaGen, a subsidiary of Grifols, announced the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company's recombinant hyperimmune polyclonal antibody drug designed to provide passive immunity to COVID-19 patients. GIGA-2050 is comprised of more than 12,000 antibodies demonstrating strong neutralizing activity against natural SARS CoV-2 variants in laboratory studies, including the delta variant and other variants that have emerged globally since the beginning of the pandemic. GIGA-2050 encompasses the full diversity of anti-coronavirus antibodies captured from the convalescent serum of 16 exceptional responders to COVID-19.

10:14 EDT PubMatic shares climb after Q2 earnings beat consensus estimates - Shares of PubMatic (PUBM) are in focus on Wednesday after the company reported quarterly earnings after the market close on Tuesday. EARNINGS: For its second fiscal quarter, PubMatic, a sell-side platform for digital advertising, said its GAAP earnings per share was 18c per share, beating analysts' consensus estimates of 8c. Revenue for the quarter was $49.7%, also exceeding the $45.05M consensus. Net dollar-based retention was 150% for the trailing twelve months ended June 30, an increase from 107% in the comparable trailing 12 month period a year ago, and adjusted EBITDA was $18.6M compared to $4.9M in the same period a year ago. "We delivered another great quarter, benefiting from a differentiated business model, multiple organic growth drivers, prior period investments, and accelerated digital ad spend," said Rajeev Goel, co-founder and CEO at PubMatic. The company also noted that it processed 20.2T impressions in Q2, a 96% increase over a year ago. OUTLOOK: For the third quarter, PubMatic expects revenue of $51M-$53M, or 35%-39% growth over 3Q20, against analysts' expectations of $46.58M. The company sees adjusted EBITDA of $15M-$16M, representing a 30% margin. For FY21, PubMatic now expects revenue to be $205M-$209M, up from its prior outlook of $195M-$200M, and better than the $197.87M analysts currently expect. Adjusted EBITDA is forecast to be $65M-$68M, above the prior outlook of $54M-$58M, and PubMatic sees achieving an adjusted EBITDA margin of approximately 30%-32%. PubMatic expects FY22 revenue growth of 25% year-over-year, and sees an adjusted EBITDA margin of about 30%. RAYMOND JAMES UPGRADE: Raymond James analyst Aaron Kessler upgraded PubMatic to Outperform from Market Perform with a $43 price target. PubMatic reported strong Q2 results, with revenue and EBITDA above expectations, driven by mobile and video strength, and guidance was also strong for the remainder of 2021, Kessler tells investors in a research note. The analyst sees PubMatic benefiting from the continued ad market strength and consolidating share in the open-web SSP market. PRICE TARGET LOWERED: KeyBanc analyst Justin Patterson lowered the firm's price target on PubMatic to $50 from $55 to better align valuation multiples with peers, while keeping an Overweight rating on the shares. The analyst notes that PubMatic's traction with supply path optimization, mobile, and video is driving faster growth into 2022 and a new annual growth profile. He suspects this outlook may receive some skepticism as few companies have issued 2022 guidance. However, with about 65% of PubMatic's revenue coming from high growth areas and SPO deals providing visibility, Patterson believes the outlook is achievable. RBC Capital analyst Matthew Swanson raised the firm's price target on PubMatic to $47 from $43 and keeps an Outperform rating on the shares. The company reported a "strong" first half half for 2021 with outperformance in its top line flowing through to profitability, the analyst tells investors in a research note, adding that he remains impressed with company specific-tailwinds in SPO driving impression growth of 96%. PRICE TARGET LOWERED: Oppenheimer analyst Brian Schwartz lowered the firm's price target on PubMatic to $45 from $50 on decline in peer valuations, while keeping an Outperform rating on the shares. The analyst notes that PubMatic reported "impressive" Q2, raised fiscal year 2021 guidance and provided fiscal year 2022 guidance above Street. PRICE ACTION: In morning trading, shares of PubMatic are up 0.6% to $34.38.

10:00 EDT Canada Goose falls -12.9% - Canada Goose is down -12.9%, or -$5.75 to $38.69.

10:00 EDT On24 falls -29.0% - On24 is down -29.0%, or -$9.36 to $22.95.

10:00 EDT FuboTV rises 14.2% - FuboTV is up 14.2%, or $4.06 to $32.70.

09:50 EDT Unity Software to acquire Parsec for $320M in cash - Last night, Unity anounced it has entered into a definitive agreement to acquire Parsec, "which allows gaming and creative professionals to work together from anywhere." Under the terms of the agreement, Unity will acquire Parsec for approximately $320M in cash. The proposed acquisition is expected to close during Unity's third quarter and is subject to customary closing conditions. "This transaction is an important step toward Parsec's and Unity's expanded cloud vision: that creators should expect to be able to work from any location, on any device through rich and powerful tools and seamless cloud infrastructure to deliver the real-time 3D experiences of the future... The work of game development and creative professionals is high fidelity, interactive and immersive, and only getting more complex as creators shift to RT3D. With companies and their employees transitioning to hybrid working and collaboration models, Parsec allows creators to be untethered from the office by meeting the unique requirements to support this level of performance processing no matter the location, device or platform. This means delivering low latency, ultra-high definition desktop streaming while providing rich detail with the same sampling rate for all images, such as 4:4:4 color space. Additionally, Parsec offers the privacy, security, quality of life and management tools needed for companies to support fleets of computing resources for all of their creators," the company stated. Reference Link

09:47 EDT Freyr Battery falls -26.3% - Freyr Battery is down -26.3%, or -$3.48 to $9.76.

09:47 EDT Joby Aviation rises 7.7% - Joby Aviation is up 7.7%, or 77c to $10.80.

09:47 EDT FuboTV rises 15.2% - FuboTV is up 15.2%, or $4.35 to $32.99.

09:41 EDT AstraZeneca says working with partner FibroGen, FDA on next steps for roxadustat - The U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for roxadustat for the treatment of anaemia of chronic kidney disease in both non-dialysis dependent, or NDD, and dialysis-dependent, or DD, adult patients, confirmed AstraZeneca (AZN). "The CRL requested an additional clinical trial on the safety of roxadustat in both the NDD and DD patient populations. AstraZeneca is working with its partner FibroGen (FGEN) and the FDA to evaluate next steps. The safety and efficacy of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, have been demonstrated in the Phase III programme including more than 8,000 patients and published in five peer-reviewed journal articles. Roxadustat is approved in a number of countries, including China and Japan, for the treatment of anaemia in CKD in NDD and DD adult patients. It is under regulatory review in other jurisdictions, including in the European Union, where it has recently received a positive CHMP opinion," the company stated.

09:18 EDT Verizon Business advances BlueJeans Telehealth - Verizon Business announced that BlueJeans Telehealth, a purpose-built, HIPAA-ready virtual care solution to help drive better patient interactions, now includes features and integrations to enhance virtual encounters with a more rounded view of the patient's health. The new Televisit Tile and integration with the Apple Health app allow patients to share specific categories of health data like heart rate, sleep, falls, and more with their provider during telehealth appointments for more informed conversations, while providing patients with control over which data they choose to share. BlueJeans Telehealth now features a new Televisit Tile that compiles and displays encounter-specific information collected during the visit. The Tile displays patient-entered symptom data and will support information and document sharing to ensure communication exchange with healthcare providers. BlueJeans Telehealth works across mobile and desktop devices and includes single-touch, download-free access to mitigate potential technology challenges. "The future of virtual healthcare is dependent on connectivity and the ability to drive real-time insights and deliver care through connected health," said Krish Ramakrishnan, Chief Innovator and Strategist, BlueJeans by Verizon. "By empowering patients to share this level of contextual information directly into the BlueJeans Telehealth visit, we are enabling patients and healthcare providers to have more meaningful conversations and successful virtual consultations that can lead to better patient outcomes."

09:13 EDT Hippo announces new issuing carrier relationship with Ally Financial - Hippo (HIPO) announced a new issuing carrier relationship with Ally Financial Inc. (ALLY) subsidiary, Motors Insurance Corp., which is a 50 state carrier. The deal will strengthen and double Hippo Insurance Services' insurance underwriting capacity, becoming Hippo's largest managing general agent unaffiliated program to date. "By working with Ally, we are bringing significant growth and diversification to our business, offering Hippo's protective insurance products to more homeowners across the country," said Rick McCathron, president at Hippo. "Our innovative and proactive approach aligns perfectly with Ally's customer-centric mission to serve the needs of the customer and help protect people's financial future, which includes their most valuable financial asset: the home. We're thrilled to be working with such a prestigious financial institution and are excited to have their support as we build the home insurance company of the future." The agreement with Ally expands Hippo's book of business across multiple partners and substantiates the MGA portion of Hippo's business separate from its carrier business through Spinnaker, maintaining a capital light model with sophisticated underwriting guidelines and pricing models. The new relationship will initially launch in 10 states and then roll out nationally.

09:11 EDT Amazon invests $1.5B in Air Hub at Cincinnati/Northern Kentucky airport - Amazon announced the beginning of Amazon Air Hub operations at the Cincinnati/Northern Kentucky International Airport, or CVG. After more than four years of planning and construction, the Amazon Air Hub will serve as the central hub for Amazon Air's U.S. cargo network, facilitating the rapid transport of customer packages across the country. This $1.5B investment in Northern Kentucky will eventually create thousands of jobs for people from various backgrounds, including load planning, management of package sortation, and robotics technology. All regular, full-time employees will have access to Amazon's wages of up to $19.50 per hour; benefits including medical, vision and dental; and a 401(k) beginning on day one. The 800,000-square-foot sortation building sits on an over 600-acre campus that features seven buildings, an expansive new ramp for aircraft parking, and a multi-story vehicle parking structure. The sortation facility is equipped with the innovative use of robotics technology that helps move and sort packages-including robotic arms and mobile drive units that transport packages across the building-miles of interlinked conveyors, and ergonomic workstations that support a comfortable work environment for employees. The building will also feature a solar rooftop scheduled for installation over the next year, and all energy generated from the panels will feed directly into the electrical grid of the local community.

09:09 EDT Momentive expands market research panel to reach B2B, healthcare audiences - Momentive announced an expansion of the company's market research targeting capabilities to meet the growing demand from business-to-business customers. Market research firms Dynata and Schlesinger Group will expand the Momentive panel-which previously offered instant access to over 144M respondents worldwide-by several million more in B2B research, enabling Momentive customers to use more granular targeting criteria for B2B audiences. This expanded capability is available now for Momentive customers. "We know from working with our clients that true insights come from real people, vetted and verified, that fit the purpose of a research project," said Michael Sanfelippo, senior vice president of customer experience at Dynata. "Dynata's rich B2B and healthcare panels are built to deliver the precise audiences needed for meaningful, impactful insights. Those panelists - from C-level to operational and clinical leaders - are qualified using proprietary automated and manual processes to ensure they are real, qualified and responsive, and will deliver a depth and breadth that will help Momentive's clients uncover the insights they need to power optimal decision-making."

09:07 EDT Comtech gets $1M contract from U.S.based tier one network operator - Comtech announced that during its fourth quarter of fiscal 2021, it was awarded a contract for approximately $1.0 million for operations support features and enhancements supporting 5G applications with a major tier-one mobile network operator in the United States. "Comtech is dedicated to supporting 5G technologies for our customers worldwide," said Fred Kornberg, Chairman of the Board and Chief Executive Officer of Comtech Telecommunications Corp. "Our long-term relationship with this customer demonstrates their trust in us to support them through the next steps in this technology."

09:06 EDT Sorrento, Dyadic enter binding term sheet for DYAI-100, C1 technology - Sorrento Therapeutics (SRNE) and Dyadic International, Inc. (DYAI) announced the signing of a binding term sheet to enter into an exclusive license agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic's lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadic's proprietary and patented C1-cell protein production platform. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties. Consideration includes a $10 million upfront payment, reimbursement of certain DYAI-100 R&D expenses, with potential for multiple future development milestones and royalty payments.

09:05 EDT Farmmi wins multi-product order from U.S. - Farmmi's subsidiary Zhejiang Forest Food won a multi-product order from a long-term customer for its dried whole and sliced mushrooms, and dried black fungus. The customer will export Farmmi's products to the United States.

09:04 EDT Rush Street Interactive invests in, enters partnership with Boom Entertainment - Rush Street Interactive announced that it has made a minority investment in Boom Entertainment, a game developer and technology provider that has created and operated sports gaming apps in the United States on behalf of numerous brands. In addition to the investment, RSI and Boom have entered into a commercial agreement. As part of that agreement, Boom will integrate its remote gaming server and license online casino and sports betting games for RSI to make available to its real money and social casino players via RSI's proprietary online gaming platform. Boom will also develop certain custom games for which RSI will have exclusivity rights on for at least one year, ensuring RSI will be able to offer its players unique and differentiated games to play. Additionally, through Boom's relationship with certain land-based casinos in Louisiana, Mississippi, and New Mexico, RSI will receive market access opportunities to operate online casino and sports betting in those new states, subject to license availability, state law and regulatory approvals. In Louisiana, RSI expects to launch mobile sports betting operations during the upcoming football season following the legalization of sports betting in the state in June.

09:03 EDT Jones Lang LaSalle acquieres proptech company Skyline AI - JLL has reached an agreement to acquire Skyline AI, an artificial intelligence technology company using proprietary machine learning models in the origination and analysis of real estate opportunities. The transaction is expected to close shortly, following completion of customary closing conditions. Skyline AI was founded in 2017 by serial technology entrepreneurs Guy Zipori, Amir Leitersdorf, Iri Amirav and Or Hiltch. JLL global venture fund JLL Spark has been an investor in Skyline AI since 2018.

09:02 EDT Willis Towers Watson selects Kristy Banas as new Chief Human Resources Officer - Willis Towers Watson announced that it has selected Kristy Banas as the company's new chief human resources officer. Banas currently serves as Willis Towers Watson's global talent advisor for Human Capital and Benefits and recently was the Global Sponsor of human resources (HR) integration planning. She will assume the CHRO role on August 16, 2021 and succeed Anne Bodnar who remains the company's chief administrative officer. Banas's career with Willis Towers Watson began in 2011. Most recently, she led global HR teams responsible for workforce planning and talent engagement, as well as for colleague development, retention, coaching and advising.

08:58 EDT Immersion expands license deal with Stanley Electric for automotive products - Immersion announced that it has expanded its license with Stanley Electric for the use of haptics in the automotive market. "Stanley is a leading global supplier of lighting products and electronic components, including automotive electronics products and control panels for printers. "Many new car models are adopting haptics across various interfaces throughout the cabin. This new wave of adoption is enabled by technology advancements that deliver high-fidelity and high-definition experiences," said Nobumitsu Shimada, Sr. Director, APAC, Immersion. "We are pleased that Stanley has expanded licensing of our patented technology," noted the company in a statement.

08:53 EDT Osino Resources reports drill results from Twin Hills Gold Project - Osino Resources announces further results from the infill and expansion drill campaign at the Twin Hills project, Namibia. There are currently 7 diamond and 3 RC rigs on site to complete the infill and expansion drill campaign by November 2021. A total 70,000m of in-fill and expansion drilling has been completed to date on the three zones of mineralization at Bulge, Twin Hills Central and Clouds East - which together make up the Twin Hills gold resource. The drilling is focused on converting the bulk of the resource to the Measured and Indicated categories as well as expanding the mineralization down dip. As expected, the infill drilling has filled in several gaps in the previous grade shell and will add greater confidence to the next iteration of the Twin Hills mineral resource. The campaign of expansion drilling has taken the mineralization at Clouds East from 150m to over 200m below surface and the deep drilling at Bulge indicates that the deposit is open below 400m. The recent drilling at Clouds East confirms that the grade and width of mineralization improves with depth and indicates the potential to increase the size of the resource at this orebody. Hole OKD148 returned an intercept of 50m @ 1.82g/t Au at approximately 200m below surface while OKD211 returned 41m @ 1.27g/t Au at 100m below surface. Higher up-dip, this same mineralized zone is much narrower and only returned an intercept of 16m @ 1.31g/t Au clearly illustrating the increasing size of the ore shoot with depth. Several additional holes are currently being drilled along strike to define this high-grade zone at depth. A hole at the northeastern corner of Clouds East appears to have just clipped the top of the high-grade shoot and returned 5m @ 7.86g/t Au, indicating that the high grade extends in this direction as well. The section through Clouds East in Figure 1 above indicates the parameters used in Osino's Technical Report describing the Twin Hills Gold Project, Namibia, dated effective April 1, which describes the Twin Hills Mineral Resource Estimate. The greywacke syncline constraining the mineralization model is represented in dark blue and the grade shell which contains 0.4g/t Au and higher, is shown in orange Since publishing the MRE, the infill drilling has identified extensive additional mineralization at Clouds East that is likely to increase the size and grade of the mineralization within the grade shell, to be included in the next resource update. The current MRE pit shell and the PEA pit design with benches are indicated on the section. The width and grade of the deeper mineralization discovered during the current phase of infill and step out drilling is likely to increase the depth of the pit bottom. The infill drilling at Twin Hills Central is nearing completion with the dense drill spacing resolving the mineralized deposit into a series of high grade, northeast plunging shoots, surrounded by lower grade material. The Twin Hills Central drilling, together with the additional infill and step-out drill assays received. Of particular note is the shallow nature of the mineralization particularly at THC where some of the higher-grade shoots come close to surface below the calcrete cover, which is only about 5m thick at OKR307 as opposed to the average calcrete thickness of 20m over most of the remainder of the deposit.

08:49 EDT Omniq AI systems to be deployed at the border check point between Israel, Jordan - OMNIQ announced it has received an order to deploy its AI-based machine vision solution at the border checkpoint between Israel and Jordan. OMNIQ's AI-based machine vision VRS solution uses patented Neural Network algorithms that imitate human brains for pattern recognition enabling quick decision-making. "This order to deploy our AI technology in a sensitive spot between Israel and Jordan is an additional vote of confidence from one of the most demanding authorities in the world. This passage, which opened after signing the peace agreement between Israel and Jordan in 1994, is the main passage point between Israel and Jordan. The momentum in the market acceptance for our AI based solution continues with our recent winnings for Homeland Security, Parking and Smart Campus management projects," said Shai Lustgarten, CEO of OMNIQ. "This reassurance of the quality and innovation of our solution follows a recent stream of awards to deploy our AI solutions at the Cypress College in California, the Georgia State University, in the City of Watkinsville, Georgia, in the Philadelphia International Airport and in a Multibillion dollar Medical Center. Our recent acquisition of Dangot Computers adds capabilities to the omniQ offering. Such that expands our solutions further and serves our existing and new customers better. Dangot Computers is a pioneer in bringing automation to Enterprise's operations, restaurants, hospitals, logistic centers and retailers. Recently, we announced the winning of a purchase order for self ordering kiosks for the largest Coffee Chain in Israel with a few branches in North America. Forbes magazine projects that the Self Ordering market can reach $30.8B by 20241."

08:45 EDT CAE raises 2021 CapEx view to $250M from $100M

08:43 EDT Dorman Products announces 571 new products - Dorman Products is announcing the release of 571 new replacement auto parts, including 60 aftermarket-first solutions, giving repair professionals and vehicle owners greater freedom to fix a wide range of cars and trucks. This month's new solutions include upgraded, braided stainless steel, flexible fuel lines for more than 2M Chevrolet and GMC trucks. Corroded fuel lines can be tough to replace because they usually require routing rigid metal lines under the vehicle. These Dorman OE FIX lines are braided stainless steel over flexible PTFE tubing, made to specific length for extended cab GMC Sierra and Chevy Silverado pickups, with new brackets and factory connectors for a better installation experience. Their flexibility also makes them easier to stock on warehouse shelves, taking up a fraction of the normal fuel line footprint. Another replacement this month is a radiator shutter assembly, also known as an active grille shutter, for more than 1.5M Ford trucks. Dorman now has 40 replacements in this category, the need for which is expected to increase in coming years as more vehicles are released with this new technology to meet fuel efficiency standards.

08:41 EDT Dyadic, Sorrento announce binding term sheet to enter License Agreement - Dyadic International (DYAI) and Sorrento Therapeutics (SRNE) announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic's lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadic's proprietary and patented C1-cell protein production platform. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties. Mark Emalfarb, Dyadic's President and Chief Executive Officer noted, "We are delighted to have executed a binding term-sheet with Sorrento Therapeutics to license the C1 technology for the development and commercialization of coronavirus vaccines, therapeutics, and diagnostics, including COVID-19. This marks a significant milestone in our corporate development efforts as we expect the license agreement we will enter into to enable us to monetize our internal COVID-19 development efforts with a partner that has the resources and expertise to advance vaccines, therapeutics, and diagnostics both clinically and commercially."

08:39 EDT BTCS adds Tezos staking to blockchain infrastructure operations - BTCS announced it has added Tezos to its blockchain infrastructure operations. Founded in 2014, XTZ is a decentralized blockchain designed for smart contracts and decentralized applications. XTZ has a $2.75 billion market cap making it the number 45th ranked cryptocurrency. It raised $232 million in 2017 in what was considered one of the largest offerings at the time. XTZ's governance mechanism allows users to vote through a Liquid Proof-of-Stake consensus mechanism called "baking". Users either become bakers or delegate XTZ, the native token of Tezos, to other bakers to earn newly-minted XTZ rewards from the protocol. To get started, BTCS has deployed its own XTZ baker nodes. There are over 400 bakers currently securing the network, and 135 projects building on XTZ, ranging from dApps to Decentralized Finance to Non-Fungible Tokens.

08:38 EDT RaiaDorgasil selects Manhattan Active Transportation Management - Manhattan Associates announced that RaiaDrogasil has chosen Manhattan Active Transportation Management to consolidate and optimize its entire logistics operations. The first phase of the implementation will be complete in just 10 weeks at RaiaDrogasil's Sao Paulo, Brazil distribution center in Q4 of 2021.

08:37 EDT Predictive Oncology adjourns special meeting of stockholders - Predictive Oncology announced that the Company's Special Meeting of Stockholders, which was convened at 3:00 p.m. Central Time on August 10, 2021, has been adjourned for the purpose of soliciting more votes on the proposal to approve an amendment to the Company's certificate of incorporation to increase the number of authorized shares of Company common stock from 100,000,000 to 200,000,000. The Special Meeting has been scheduled to reconvene on August 17, 2021 at 3:00 p.m. Central time at the offices of Maslon LLP, 3300 Wells Fargo Center, 90 South Seventh Street, Minneapolis, MN 55402. The other proposals that were voted on at the Special Meeting were all approved by the requisite votes of the stockholders, including an amendment to the Amended and Restated 2012 Stock Incentive Plan to increase the reserve of shares of common stock authorized for issuance thereunder by 1,500,000, to 3,250,000; the issuance of additional shares of common stock of the Company pursuant to a previously approved equity line of credit arrangement; ratification of the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021; and a proposal to adjourn the Special Meeting, if necessary, to solicit additional proxies for approval of the Charter Proposal or any of the other proposals as applicable, in the event that there are not sufficient votes at the time of the Special Meeting to approve any such proposal. During the period of the adjournment, the Company will continue to solicit proxies from its stockholders with respect to the Charter Proposal. Proxies previously submitted in respect to the Special Meeting with respect to the Charter Proposal will be voted at the reconvened meeting unless properly revoked.

08:35 EDT SG ECHO in collaborative effort with ATCO Structures &Logistics - SG Blocks announced that SG ECHO would be engaging in a collaborative effort with ATCO Structures & Logistics, a one-stop provider of integrated energy, housing, transportation and infrastructure solutions. ATCO has committed 20 units to be produced by SG ECHO as a part of a national roll out of modular fleet units throughout the U.S. With this, SG ECHO has the opportunity to continue providing ATCO with ongoing support through this initiative, which will require continued production over a number of years. Plans are to produce in volumes with larger, more scalable orders as needed. "We're pleased to have started the project and for a company whom we have great respect," Paul Galvin Chairman and CEO noted. "It's satisfying to provide modular structures to assist an organization who believes in the capability of modular construction just as much as we do." The initial units are to be delivered in Q3 of 2021. Company will continue to keep updated as the status progresses.

08:34 EDT Mogo raises Q4 subscription and service revenue growth view to 100%-110% - The company states: "We expect year over year growth of 100% to 110% in subscription and services revenue in Q4 2021, compared to previously communicated target of 80% to 100% growth. We expect total revenues of C$70M to C$75M in FY22. We expect improving adjusted EBITDA margin as a percentage of revenue beginning in FY22."

08:33 EDT Telos announces launch of Xacta 360 1.7 - Telos announced the launch of Xacta 360 1.7, the latest version of its cyber risk management and compliance analytics platform. This version introduces Essential Data Exchange, an Xacta 360 capability that supports a variety of standards that automate the sharing of compliance data among organizations and applications for more efficient, less laborious compliance management, reporting and audit collaboration. "Telos is proud to be at the forefront of supporting data-driven compliance in our Xacta solutions through EDE," said Rick Tracy, CSO and Xacta product manager, Telos. "These data-sharing capabilities will allow our customers to collaborate on cyber risk and compliance management activities more efficiently and accelerate reciprocity when submitting security packages, performing assessments and audits, and transferring crucial body of evidence data in a tool-agnostic format." EDE currently supports three compliance data-sharing standards: NIST's Open Security Controls Assessment Language standard, which has been adopted by the FedRAMP cloud compliance program; BoE.xml, used by the Intelligence Community; and Xacta Data Exchange, used for audit collaboration.

08:31 EDT T. Rowe Price reports preliminary AUM $1.64T at July 31 - Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $0.3B in July and $15.1B for the year-to-date period ended July 31. These client transfers include $0.2B and $11B, respectively, transferred to the target-date retirement trusts during July and the year-to-date period.

08:31 EDT Joby Aviation comes public after closing Reinvent Technology Partners deal - Joby Aviation, a California-based company developing all-electric aircraft for aerial ridesharing, announced last night that Joby Aero, Inc. completed its previously announced business combination with Reinvent Technology Partners (RTP), a special purpose acquisition company. Upon the completion of the transaction, RTP changed its name to "Joby Aviation, Inc." Joby's common stock and warrants will commence trading on the New York Stock Exchange on August 11, 2021, under the ticker symbols "JOBY" and "JOBY WS," respectively. The transaction values Joby at $4.5B enterprise value, with proceeds raised plus cash on the balance sheet as of March 31, 2021 equaling approximately $1.6B. The proceeds are expected to fund Joby through initial commercial operations. Reid Hoffman, LinkedIn Co-Founder and Co-Lead Director of RTP, said, "With its advanced technology, we believe Joby is 'Tesla meets Uber in the air' and the clear leader in the eVTOL and aerial ridesharing space. We believe Joby is well-positioned with capital to be the first company to certification and commercialization. Closing this business combination accelerates Joby's roadmap, and we look forward to supporting JoeBen and Joby's world-class team in executing on their vision." JoeBen Bevirt, founder and CEO at Joby, said, "By taking Joby public we have the opportunity to drive a renaissance in aviation, making emissions-free flight a part of everyday life. This is our generation's moonshot moment, and at Joby we're proud to be leaning in."

08:27 EDT Borqs Technologies announces strategic investment, collaboration with Zippie - Borqs Technologies has signed an agreement with Zippie, a blockchain application and payment platform company headquartered in Singapore, to jointly develop solutions for IoT autonomous payments to service the rising demand for digital currency transactions. So far Zippie has three applications on its platform: MyPlanet - a donation application for full end-end transparency donation platform for conservation projects. Lohko wallet - a platform for investors to manage their digital assets. Lohko's first available products are physical gold and silver bars. AirImpact - a dashboard for corporates to manage their value transfer.

08:25 EDT Advaxis announces Nasdaq grant of extension to regain compliance - Advaxis announced that it has received a letter indicating that following the Company's hearing before the Nasdaq Hearings Panel, the Panel determined to grant the Company an extension through November 22, 2021, to comply with Nasdaq's $1.00 Minimum Bid Price Rule and complete its previously announced merger transaction with Biosight. On July 6, 2021, Advaxis announced that it had entered into a merger agreement with Biosight, a privately held, Israel-based pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders. Pursuant to the Nasdaq Listing Rules, the combined company will be required to meet all applicable initial listing requirements upon the closing of the merger, including the $4 per share price requirement. While there can be no assurance, the Company believes that it will be able to close the merger and demonstrate compliance with all applicable requirements for initial listing on The Nasdaq Capital Market on or before November 22, 2021.

08:23 EDT Whitestone REIT highlights trends in markets it has invested in - Whitestone highlighted several 'positive' trends in the high growth markets where Whitestone has prioritized its investments. Over the past several years, metropolitan areas in Arizona and Texas have experienced some of the highest economic activity and population growth in the United States. Whitestone's properties continue to attract outstanding tenants that offer essential services and goods needed by local communities in these areas, driving strong growth and value for shareholders. The company's long-term strategy of acquiring and developing premier properties in these rapidly expanding regions continues to deliver value for all stakeholders, including the many communities in which Whitestone operates. Migration tailwinds have driven increased quarter-over-quarter foot traffic - a 17.9% increase in foot traffic at its centers from 4Q2020 to 2Q2021 - for Whitestone's tenants and new leases across Whitestone's properties. This is evidenced by the company's first and second quarter 2021 leasing activity, occupancy levels, leasing spreads and average base rent on leased square foot. Whitestone's new tenant square foot leasing activity for the first six months of 2021 has been 100% higher than the first six months of 2020 and 40% higher than the first six months of 2019. "Since the IPO of Whitestone in 2010, we have had conviction in the Sun Belt markets, and most specifically Arizona and Texas," said Jim Mastandrea, Chairman and Chief Executive Officer of Whitestone REIT. "Guided by our local expertise and consumer-driven data, our portfolio and investment strategy ensure we own properties in high-growth markets where people increasingly want to live. As a result of the pandemic, these years-long migration trends have accelerated and the prescient work of our team in thoughtfully positioning each of our properties has delivered outsized value for all of our stakeholders." Mr. Mastandrea continued, "Our strategically chosen markets are resilient, our tenants serve their local neighbors' essential lifestyle needs, and our business model generates consistent and attractive cash flow and returns. Change creates opportunity. In retail and real estate, we are excited by the many opportunities created by both population and corporate migrations and the increased demand for consumer-oriented centers and services, which Whitestone provides."

08:20 EDT Clever Leaves announces commitment to University of Missouri - Clever Leaves announced their first official letter of support to the University of Missouri's translational pediatric neuroscience lab providing CBD isolate product for an upcoming National Institutes of Health proposal. This marks the second research team supported for a proposal under Clever Leaves' Project Change Lives Campaign, following an initial sponsored study that was announced in collaboration with UC Davis' Plant Sciences Department last week, whereby the Company has committed to providing up to $25M in cannabis- derived ingredients and finished products for use in high-quality research that will advance the field of medical cannabis in the United States. Active research projects by this study team include advancing understanding of CBD for the treatment of: Autism spectrum disorder; Genetic disorders; Rare Epilepsies; Pain management; Cognitive disorders; and Inflammation. "As one of the first sponsored research partnerships under Clever Leaves' new Project Change Lives campaign, it is important that we partner with a highly credentialed university and research team such as the University of Missouri to validate our strong commitment to advancing the understanding of medical cannabis domestically by providing our pharmaceutical-grade cannabinoids to researchers in the U.S.," said Kyle Detwiler, CEO of Clever Leaves. "The basic and clinical research findings emerging from Mizzou's Child Neurology Division are aimed at providing the foundational knowledge on which many of medicine's next generation of treatment options could be developed. Accordingly, this ongoing research is directly in-line with Clever Leaves' goal to change lives through the research and development of new cannabis therapies."

08:18 EDT In8bio completes dosing of first cohort in Phase 2 trial with Allogeneic - IN8bio announced completion of dosing of the first patient cohort in a Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant. The three patients comprising the first cohort did not experience any severe adverse infusion reactions or dose limiting toxicities to date. The first two patients are at 14.5 months and 12.2 months, respectively, post-HSCT as of June 30, 2021, and continue to be in complete remission. "For patients with high-risk leukemia, the availability of HSCT is a path toward a potential cure, but rates of leukemic relapse remain high," said William Ho, Chief Executive Officer and co-founder of IN8bio. "Research by our Chief Scientific Officer, Dr. Lamb, and others has shown that that high numbers of circulating gamma-delta T cells have been correlated with improved survival outcomes in these patients. Our goal with INB-100 is to generate an anti-leukemic effect by supplementing patients' immune systems with allogeneic gamma-delta T cells to reduce relapse and improve overall survival in patients who have undergone an allogeneic HSCT. Although early, we are encouraged by data obtained to date indicating the potential for well-tolerated allogeneic gamma delta T-cell therapies. We look forward to announcing additional data on this program in 2022."

08:17 EDT Acutus Medical receives FDA clearance, CE mark for AcQMap 8 - Acutus Medical announced its innovative suite of software upgrades, known collectively as AcQMap 8, has received FDA clearance and been awarded CE Mark. AcQMap 8 introduces advanced new mapping algorithms into Acutus' foundational technology, the AcQMap 3D imaging and mapping system. These algorithms - including AcQTrack and the SlowZone Locator - are designed to highlight regions of interest during the mapping and ablation of complex atrial arrhythmias, the treatment of which has been shown to significantly improve patient outcomes. The software upgrade also features a series of procedural workflow enhancements and seamless integration of Acutus' therapeutic ablation technologies, where currently available. AcQMap 8's software enhancements also facilitate the integration of Acutus' AcQBlate FORCE Sensing Ablation Catheter and System into the AcQMap system, enabling complete visualization and configuration of ablation procedures directly on the AcQMap system's user interface. "Our goal is to give physicians the tools they need to efficiently and effectively treat complex arrhythmias like atrial fibrillation," said Vince Burgess, President and CEO, Acutus Medical. "We continue to push the boundaries of what's possible in the EP lab and take significant technological strides designed to improve patients outcomes. AcQMap 8's unique automated mapping algorithms and functionalities are a much-needed next step as we continue to drive innovation in the electrophysiology space and help physicians create optimized and personalized treatment strategies for all of their patients."

08:15 EDT Xperi unit TiVo renews product and patent pact with Panasonic - TiVo, a wholly-owned subsidiary of Xperi Holding Corporation announced the renewal of its product and patent license agreements with Panasonic . Panasonic signed a new multi-year extension of the company's products for the Japan market, including G-Guide, G-Guide HTML and G-Guide xD, enabling Panasonic to continue providing advanced entertainment discovery experiences across its TV, DVR and set-top box products. The agreement also commits Panasonic to deploying the newly released OTT-Link functionality that enables consumers to deep link directly into content from within G-Guide, TiVo's market leading content discovery solution for Japan.

08:12 EDT Singing Machine announces minority investment by Stingray Group - The Singing Machine today announced that Stingray Group has participated in the Company's recent private placement offering to obtain a minority stake in Singing Machine and will be accepting a seat on the company's newly reconstituted board of directors. "Stingray and Singing Machine have been long-time friends and partners with a shared passion for connecting people through music," said Eric Boyko, President, Co-founder and CEO of Stingray. "We are thrilled to invest in Singing Machine and secure access to its important karaoke distribution channel, leverage its products and consequently increase Stingray Karaoke downloads and revenues. This transaction demonstrates our intent and ability to act as an industry leader."

08:11 EDT Summit Therapeutics to combine Phase III trials of ridinilazole - Based on a thorough review of the design and enrollment status of two ongoing blinded Phase III Ri-CoDIFy trials, Summit Therapeutics announced that it will combine its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus vancomycin into a single study. Ridinilazole, a novel first-in-class drug, is currently under investigation for use as first-line therapy for the treatment of initial and recurrent Clostridioides difficile infection. The trial's primary endpoint seeks to prove ridinilazole's superiority in sustained clinical response as compared to vancomycin. Ridinilazole is not currently approved for use by any regulatory authority. Current enrollment in the two Ri-CoDIFy Phase III trials is 753 patients, split approximately evenly between each of the two trials. This enrollment level offers a unique opportunity to combine the studies, as the two ongoing trials have enrolled just over 50% of their targeted goal, are still blinded, and allow for a prospectively planned analysis. The ridinilazole clinical program commenced with the Phase I trial beginning in 2012, a 100-patient Phase II clinical trial began in 2014, and the current Ri-CoDIFy Phase III clinical trials enrolled the first patient in February 2019. The company recently released breakthrough Phase II clinical study data, including the relative sparing of ridinilazole on the gut microbiome as compared to vancomycin, ridinilazole's minimal impact on the gut resistome, and its novel mechanism of action. This effort is funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, under contract number HHSO100201700014C.

08:08 EDT Concordium, Swvl partner on blockchain-based mass transit systems - Concordium and Swvl announced a strategic partnership to, for the first time, use blockchain technologies to develop transformative next generation mass transit systems. Concordium will provide a blockchain-based technology platform that aims to upgrade the mass transit travel experience for Swvl's customers. The platform is intended to help solve the highly-complex logistical challenges inherent in mass transit, while advancing Swvl's efforts at decarbonization and smart, green mobility. .

08:08 EDT Quantum appoints John Hurley as Chief Revenue Officer - Quantum appointed John Hurley as Chief Revenue Officer. Prior to Quantum, Hurley led multiple client segments at Cisco, including his most recent role as vice president, global commercial segment, where his team was responsible for driving the multi-billion dollar commercial business. Hurley also spent several years overseeing Cisco's service provider business.

08:06 EDT Easterly Government Properties names Allison Marino chief accounting officer - Easterly Government Properties (DEA) announced that Allison Marino has been appointed senior VP and chief accounting officer of the company, effective August 9. Prior to joining Carr Properties, Marino served in Marriott International's (MAR) financial reporting and analysis group.

08:06 EDT MeiraGTx provides anticipated upcoming milestones - Initiate, with Janssen (JNJ), the Phase 3 Lumeos clinical trial evaluating AAV-RGPR as a treatment for patients with X-Linked retinitis pigmentosa in the second half of 2021. Initiate a Phase 3 pivotal trial of AAV-RPE65 for patients with RPE65-associated retinal dystrophy in the second half of 2021. Complete enrollment of the Phase 1 AQUAx trial of AAV-AQP1 for the treatment for Grade 2/3 radiation-induced xerostomia in the second half of 2021. File Investigational New Drug application for AAV-GAD for the treatment of Parkinson's Disease in the third quarter of 2021. Present in-vivo data from the company's riboswitch gene regulation platform at R&D day demonstrating regulation of multiple therapeutic targets in multiple tissues in the fourth quarter of 2021. Data from the Company's proprietary promoter engineering platforms will also be presented. Advance, with Janssen, development of AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia associated with mutations in the CNGB3 and CNGA3 genes to late-stage clinical trials. Continue to progress several pre-clinical programs towards INDs in 2022.

08:05 EDT Toyota debuts mobile collision assistance service - Toyota and Lexus drivers now have a new assistance service available to them in the moments following a collision. Collision Assistance, a just-in-time support service, is now available to drivers within the Toyota and Lexus mobile app. The feature within the Toyota and Lexus Owners Apps offers guided instructions to help drivers navigate a post-collision repair process. Toyota worked with CCC Intelligent Solutions, a leading SaaS platform for the multi-trillion-dollar P&C insurance economy, to develop Collision Assistance. The CCC mobile technology combines guided accident documentation and access to claims and management services to assist drivers following a collision. Toyota transmits accident and vehicle telematics data to CCC to initiate the program. Collision Assistance is designed to let the customer choose how they'd like to handle the claim and repair processes, providing convenience and safety while also ensuring owners are informed about the process through completion.

08:04 EDT Aditx Therapeutics enters partnership with GLML to offer AditxtScore in Michigan - Aditxt announced a partnership with Great Lakes Medical Laboratory, or GLML, a full-service medical reference laboratory, to offer its AditxtScore for COVID-19 throughout the State of Michigan. The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens. This makes it possible to assess the strength of an individual's immune response to the SARS-CoV-2 virus. Under the agreement, GLML will make the AditxtScore for COVID-19 available throughout its six physical locations and mobile units in Michigan. The initiative is part of Aditxt's ongoing effort to expand its immune monitoring network nationwide.

07:57 EDT Ormat Technologies wins contract to support San Jacinto geothermal project - Ormat Technologies (ORA) announced that it has secured a contract to supply products to a 10 MW of a geothermal air-cooled Ormat Energy Converters to Polaris Infrastructure Inc. (RAMPF), a Toronto-based company engaged in the operation, acquisition and development of renewable energy projects in Latin America, for the San Jacinto facility in Telica, Leon, Republic of Nicaragua. Ormat anticipates an 11-month design, manufacture, and delivery of the OEC unit.

07:50 EDT Genetron receives full marks under NCCL's external quality assessment - Genetron announced that its Beijing clinical laboratory has received full marks under the National Center for Clinical Laboratories', or NCCL, first nationwide, external quality assessment of NGS-based comprehensive genomic profiling for solid tumors. "The clinical laboratory passed the assessment with flying colors, earning the designation "Outstanding Laboratory" and receiving full marks, ranking first among all of the 63 laboratories that participated in the evaluation," the company said. In order to improve clinical laboratories' NGS-based comprehensive genomic profiling capabilities in China, the NCCL carried out a nationwide assessment for the first time. The assessment aims to point out various and common issues experienced by laboratories in the industry, and to improve the quality of industry practices.

07:47 EDT Helius Medical launches new website for US based patients, physicians - Helius Medical Technologies announced that the company has launched a new website, created to serve as a resource for U.S.-based patients and physicians. The website is designed to provide both audiences with information on the company's PoNS Treatment and enable them to connect with Helius to learn more information, ask questions and receive future updates. "We are pleased to expand our online resources for U.S.-based patients and physicians as we prepare to commercialize our PoNS technology during the first quarter of 2022," said Dane Andreeff, President and Chief Executive Officer of Helius. "Building on this progress, we look forward to educating and developing relationships with key clinicians, and raising awareness of our recently authorized PoNS device at the patient level, as part of our pre-commercial activities during the second half of this year."

07:44 EDT Humacyte announces publication of in vivo data on BVP - Humacyte announced laboratory and preclinical data demonstrating the potential to engineer a biovascular pancreas as a method to transplant pancreatic islet cells for the long-term treatment of type 1 diabetes have been published in the Journal of Tissue Engineering. The manuscript, entitled, "Development of a Bioartificial Vascular Pancreas," reports in vivo, in vitro and in silico data supporting the potential of the biovascular pancreas technology platform to overcome current limitations of islet cell transplantation and offer an effective way to transplant pancreatic islet cells. Humacyte is developing the biovascular pancreas, or BVP, leveraging its human acellular vessels as a vascular scaffold, to be implanted in an outpatient procedure. The published data expand upon findings presented in June 2021 at the American Transplant Congress 2021 Virtual Connect, which demonstrated that pancreatic islet cells embedded in the outer matrix of an acellular vessel can create a working BVP in preclinical models. On February 17, 2021, Alpha Healthcare Acquisition, a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175M PIPE financing agreement.

07:42 EDT Alpha Healthcare Acquisition announces publication of in vivo data on BVP - Humacyte announced laboratory and preclinical data demonstrating the potential to engineer a biovascular pancreas as a method to transplant pancreatic islet cells for the long-term treatment of type 1 diabetes have been published in the Journal of Tissue Engineering. The manuscript, entitled, "Development of a Bioartificial Vascular Pancreas," reports in vivo, in vitro and in silico data supporting the potential of the biovascular pancreas technology platform to overcome current limitations of islet cell transplantation and offer an effective way to transplant pancreatic islet cells. Humacyte is developing the biovascular pancreas, or BVP, leveraging its human acellular vessels as a vascular scaffold, to be implanted in an outpatient procedure. The published data expand upon findings presented in June 2021 at the American Transplant Congress 2021 Virtual Connect, which demonstrated that pancreatic islet cells embedded in the outer matrix of an acellular vessel can create a working BVP in preclinical models.

07:38 EDT Anterix, Federated Wireless to offer utilities integrated 900 MHz CBRS services - Anterix and Federated Wireless, a holder of licensed spectrum in the 900 MHz band throughout the U.S., are collaborating to create a new Anterix offer combining dedicated use of Anterix's 900 MHz broadband spectrum paired with Federated Wireless' shared spectrum services that facilitate use of the CBRS band. The new offering, when completed, can facilitate utility access to a multi-band solution for their grid communications deployment.

07:37 EDT Anterix, Federated Wireless Collaborate to Offer Integrated 900 MHz / CBRS Serv - Anterix and Federated Wireless, a holder of licensed spectrum in the 900 MHz band throughout the U.S., are collaborating to create a new Anterix offer combining dedicated use of Anterix's 900 MHz broadband spectrum paired with Federated Wireless' shared spectrum services that facilitate use of the CBRS band. The new offering, when completed, can facilitate utility access to a multi-band solution for their grid communications deployment.

07:34 EDT Kaleido Biosciences provides updates on upcoming milestones - Topline data from the non-IND clinical study of KB295 in patients with mild-to-moderate ulcerative colitis are expected by the end of the third quarter. Additional data from the observational clinical study of KB109 in patients with mild-to-moderate COVID-19 are expected by the end of the third quarter. In August, Kaleido announced a collaboration with the COPD Foundation that is on track to initiate a Phase 2 clinical study of KB109 in patients with chronic obstructive pulmonary disease in the first quarter of 2022.

07:32 EDT Gritstone to host KOL webinar on neoantigen oncology programs - Gritstone bio announced that it will host a key opinion leader webinar on its neoantigen oncology programs for colorectal cancer on Wednesday, August 18, 2021 at 11am Eastern Time. The webinar will feature a presentation by KOL Michael J. Overman, M.D., University of Texas MD Anderson Cancer Center, who will discuss the treatment paradigm and substantial unmet medical need of patients with colorectal cancer and the value of novel biomarkers such as ctDNA in both the design of clinical trials and the assessment of clinical benefit with cancer immunotherapy. Gritstone's Chief Executive Officer, Dr. Andrew Allen, will also speak on the company's approach to oncology through the use of tumor-specific neoantigens. These critical targets are unique to tumor cells and can be recognized and targeted for destruction by the patient's own immune system. Dr. Allen will then preview the near-term comprehensive data update being presented in September during the European Society of Medical Oncology from the Phase 1/2 GRANITE program which has completed enrollment. Long-term follow-up data on patients presented in July 2020 plus new patient data will be presented that address the key question of whether GRANITE-elicited robust CD8+ T cell responses confer clinical benefit in challenging, end-stage patients.

07:30 EDT FibroGen trading resumes

07:27 EDT Miromatrix announces key strategic investors to advance liver, kidney programs - Miromatrix Medical (MIRO) announced strategic investors involved in its Series C financing, which was followed by its June 24th IPO. The company outlined clinical initiatives and operational expansions as part of its investment plan for 2021 and 2022 focused on their liver and kidney programs. The additional funding will help accelerate Miromatrix' progress towards initiating a clinical trial of its External Liver Assist Product. The trial, which is expected to begin in the second half of 2022, will assess the function of a bioengineered liver in humans via an external application. It will serve as a milestone in the ongoing research efforts to develop fully transplantable livers and kidneys, addressing the enormous unmet need for thousands of patients in the U.S. each year. The Series C round was led by the venture capital investment arm of Baxter (BAX), with participation by CareDx (CDNA) and DaVita (DVA) as strategic investors in the Company. DaVita originally invested in Miromatrix in 2018, leading its Series B-2 round, and it also provided bridge financing for the Series C round.

07:25 EDT Clene enters into two leases to expand manufacturing capacity of CNM-Au8 - Clene, along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, announced the completion of two lease agreements that will more than quadruple the company's manufacturing capacity for its lead asset, CNM-Au8, a gold nanocrystal suspension. The first of these agreements is a ten year lease for a manufacturing space located at 100 Chesapeake Boulevard, Elkton, Maryland. The 74,210 sq. ft. building will be redeveloped to support Clene's proprietary electrochemical processes for manufacturing CNM-Au8 and will materially increase its manufacturing capacity in advance of the expected H1 2022 data release from its Phase 3 registration trial evaluating CNM-Au8 as a treatment for amyotrophic lateral sclerosis. Clene expects redevelopment to commence within weeks and plans on partial occupancy with a few months and Phase 1 of production to be underway in the first half of 2022. Simultaneously, Clene entered into a seven year lease to further expand its existing manufacturing capacity at its site located at 500 Principio Parkway West, North East, Maryland to a total of 32,229 sq. ft. This expansion enables additional R&D and manufacturing capacity for CNM-Au8 and further positions Clene to address its potential long-term needs in its efforts to treat the neurodegenerative diseases of ALS, multiple sclerosis and Parkinson's disease.

07:22 EDT Canaan to invest $3.1M in Pixelworks subsidiary - Canaan, (CAN) through its wholly-owned subsidiary, Hangzhou Canaan Creative Information, has entered into an agreement with Pixelworks Semiconductor Technology or PWSH, a subsidiary of Pixelworks (PXLW), to invest approximately $3.1M in cash in exchange for an equity interest in PWSH, subject to certain closing conditions. Canaan's investment in PWSH is under a Capital Increase Agreement that Pixelworks and PWSH entered with certain private equity and strategic investors besides Canaan, in addition to an ESOP program of PWSH. Under the Capital Increase Agreement, PWSH has also agreed to attempt to complete all requirements to qualify to file an application for a qualified initial public offering such that the QIPO is consummated prior to June 30, 2024, for the Investors. PWSH designs, manufactures and sales visual display processing semiconductors and custom application specific integrated circuits solutions for video applications, advanced media processing, and the delivery and streaming of video in the target markets of smartphones, tablets, digital projection systems, high-quality video infrastructure equipment, and over-the-air streaming devices.

07:17 EDT Kamada completes workforce downsizing in Q2 - In connection with the transition of GLASSIA manufacturing to Takeda, during the second quarter of 2021, the Company largely completed the planned workforce downsizing and incurred a one-time expense of $0.6 million related to excess severance remuneration for the employees who were laid-off as part of this downsizing. The downsizing process is expected to result in an annualized reduction of approximately 10% in overall labor costs.

07:16 EDT LG QNED Mini LED TV lineup receives WiSA ready certification - "WiSA announced that LG Electronics' recently-launched QNED Mini LED TVs, have been certified as WiSA Ready further expanding its lineup of existing WiSA Ready TV models. The launch marks the fourth WiSA Ready product family rollout from LG this year, which also includes the brand's latest award-winning LG OLED TVs and LG NanoCell TVs as well as its CineBeam laser projector. Being the first Mini LED TVs with WiSA Ready capabilities, LG's QNED Mini LED TVs easily connect to WiSA USB Transmitters, allowing seamless wireless audio and control communication with all WiSA Certified speakers from well-known brands like Bang & Olufsen, HARMAN, Klipsch, System Audio and many more. "This series truly represents the dawn of a new era for LED TVs," said Tim Alessi, LG USA's senior director of home entertainment product marketing. "Consumers can expect high-end brightness levels and support of Dolby Vision HDR, Dolby Atmos, hands-free voice control and more. We are excited to continue the momentum and bring forth new and exciting TVs that present wireless home cinema options through integrated WiSA technology,s" said the company.

07:14 EDT Royalty Pharma sees 2021 adjusted cash receipts $2.08B-$2.12B - This Adjusted Cash Receipts guidance includes a $37 million milestone payment related to Soliqua performance which is expected to be paid in the third quarter of 2021. Royalty Pharma also expects payments for operating and professional costs to be approximately 9% to 10% of Adjusted Cash Receipts in 2021. Royalty Pharma expects interest paid to be approximately $130 million for the full year of 2021. Based on the semi-annual interest payment schedule of Royalty Pharma's existing bonds, interest paid is anticipated to be $64 million in the third quarter with a de minimis amount recorded in the fourth quarter. The projection assumes no additional debt financing in 2021. Royalty Pharma anticipates the first semi-annual interest payment on the 2021 Notes to be due in March 2022 and to increase annual interest paid by approximately $36 million, resulting in total expected interest paid to be approximately $170 million in 2022. Additionally, Royalty Pharma expects other income, net, to reflect a $16 million one-time cash payment in the third quarter of 2021 related to the bond offering.

07:11 EDT Chesapeake raises 2021 total production view to 415-435 from 410-420 MBOE/d - Sees 2021 oil production 23.5-25.5 mmbbl, gas production 725-745 bcf. Pending the successful closing of the Vine transaction in Q4, Chesapeake's preliminary plan is to operate 10 to 12 rigs in 2022, with 8 to 9 rigs focused on its gas portfolio and 2 to 3 rigs concentrating on its oil assets. The company will maintain its commitment to a disciplined capital reinvestment strategy, anticipating a 2022 reinvestment rate of 50 - 60%. At NYMEX strip pricing as of July 30, 2021, this preliminary capital program is anticipated to generate between $2.55 billion to $2.75 billion in total adjusted EBITDAX. Chesapeake also anticipates this preliminary capital program will result in its average annual 2022 oil production remaining flat from 2021 fourth quarter average levels.

07:09 EDT Optinose provides FY21 guidance, upcoming milestones - XHANCE Net Revenue and Average Net Revenue per Prescription: The company expects XHANCE net revenue for the full year of 2021 to be at least $80M. In addition, the company expects full year 2021 XHANCE net revenue per prescription to be greater than $200. Operating Expenses: The company expects total GAAP operating expenses for 2021 to be in the range of $137M-$142M, of which the company expects stock-based compensation to be approximately $10 million. Chronic Sinusitis Clinical Trials: The company has completed enrollment in the first of its two clinical trials evaluating XHANCE as a potential treatment for chronic sinusitis and expects top-line results in the first quarter of 2022. The Company expects to complete patient enrollment in its second clinical trial in the fourth quarter of 2021 and to have top-line results in the second quarter of 2022.

07:08 EDT Wendy's raises share repurchase authorization by $70M - The company announced that its Board of Directors has approved an increase to the company's existing share repurchase authorization by $70M to a total of $220M. The company repurchased 1.2M shares for $27.3M in the second quarter and has repurchased 0.2M shares for approximately $4.4M thus far in the third quarter. As of the date of this release, approximately $100M remains available under the company's newly increased $220M share repurchase authorization that expires in February 2022.

07:06 EDT scPharmaceuticals expects 2021 net loss $30M-$34M - Based on its current operating plan, the Company expects its net loss for 2021 to be in the range of $30.0 to $34.0 million for the fiscal year, a decrease over prior guidance of $32.0 to $36.0 million.

07:05 EDT Viridian Therapeutics provides updates on upcoming milestones - VRDN-001: The company remains on track to file an IND in the fourth quarter of 2021, with initial proof of concept clinical data in TED patients expected in the second quarter of 2022. VRDN-002: IND-enabling activities remain on track with plans to file an IND by the end of 2021. The Company expects to initiate clinical development with a Phase 1 single ascending dose trial to explore safety, tolerability, pharmacokinetics, and target engagement of intravenous VRDN-002 in healthy volunteers. Data from this trial are expected by mid-year 2022, and could demonstrate feasibility of a low-volume and/or low-frequency dosing paradigm. In parallel, formulation development is on track to support initiation of a clinical trial evaluating low-volume subcutaneous injection of VRDN-002 in 2022. Discovery Pipeline: The Company continues to evaluate additional opportunities to expand its product pipeline for rare disease indications and remains focused on opportunities to leverage validated mechanisms and technologies to bring new therapeutic options to patients underserved by current therapies.

07:04 EDT Wendy's raises quarterly dividend 20% to 12c per share - Payable on September 15 to stockholders of record as of September 1.

07:02 EDT FibroGen: FDA will not approve roxadustat NDA in present form - FibroGen announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for roxadustat for the treatment of anemia of chronic kidney disease. The letter indicates the FDA will not approve the roxadustat NDA in its present form and has requested additional clinical study of roxadustat be conducted, prior to resubmission. Roxadustat is approved in China, Japan, Chile, and South Korea for the treatment of anemia of CKD in both non-dialysis-dependent and dialysis-dependent adult patients and has received a positive opinion from the Committee for Medicinal Products for Human Use, the European Medicines Agency's committee responsible for human medicines. The European Commission decision is expected by the end of August.

06:58 EDT Cardinal Health extends agreements with CVS Health through 2027 - Cardinal Health (CAH) announced that it has extended its agreements with CVS Health (CVS) to distribute pharmaceuticals to retail pharmacies and distribution centers through June 30, 2027. "We value our long-standing partnership with CVS Health, and we are honored to continue our important work together to bring our best-in-class abilities together for their customers," stated Mike Kaufmann, CEO of Cardinal Health.

06:54 EDT Energizer announces 75M accelerated share repurchase plan - Energizer announced it has entered into an agreement to repurchase an aggregate of $75M of its common stock in an accelerated share repurchase program with JPMorgan Chase, National Association. This equates to approximately 1.9M shares, at the closing price on August 10 and represents approximately 2.6% of Energizer's fully diluted outstanding stock. The company is expected to fund the ASR program using available cash on hand and revolver borrowings. The company will repurchase shares under the ASR Program as part of its existing 7.5M share repurchase authorization, which was approved by its board of directors in November 2020.

06:48 EDT Lazard reports preliminary AUM $278.4B as of July 31 - The month's AUM included market appreciation of $2.2B, net outflows of $1.1B and foreign exchange depreciation of $0.2B.

06:39 EDT Greif announces $70 per ton increase on URB, 8.5% increase on packaging products - Greif announced that it is implementing a $70 per ton price increase for all grades of uncoated recycled paperboard, or URB, and an 8.5% increase on all tube and core and protective packaging products. The uncoated recycled paperboard increase is effective immediately with new orders and shipments on and after September 13. This is in addition to the $50 per ton price increase implemented on July 26. The tube and core and protective packaging products increase is effective with shipments on and after September 24. This is in addition to the 6% price increase implemented on August 6. These price increases are in response to continued robust demand across the Greif paperboard network and ongoing cost pressures with raw materials, labor and transportation.

06:12 EDT ADS-TEC Energy to go public through European Sustainable Growth Acquisition deal - ADS-TEC Energy and European Sustainable Growth Acquisition Corp., a publicly traded special purpose acquisition company focused on identifying Europe-based, technology-enabled businesses that utilize green technologies, announced that they have entered into a definitive business combination agreement. Upon the closing of the transaction the combined entity will be named ADS-TEC Energy and remain listed on the Nasdaq Capital Market. A substantial portion of the proceeds from the transaction will be used to accelerate the expansion of ADS-TEC Energy's storage solutions, charging and energy management platforms in the U.S. and Europe and continue the development and enhancement of the company's existing technology platforms. To facilitate that expansion, ADS-TEC Energy intends to increase its U.S. presence and operations. The pro forma market capitalization of the combined company is approximately $580M. EUSG has also secured commitments of a fully subscribed $156M in a Private Investment in Public Equity, or PIPE, at $10 per share, that is anticipated to close one business day prior to the business combination. Investors in the PIPE include, amongst others, APG, Invesco, Polar Structure and SwedbankRobur. A portion of the proceeds from the PIPE will be used to fund the cash consideration required to effect the business combination. ADS-TEC Energy is currently 61% owned by ADS-TEC Holding and 39% owned by Bosch Thermotechnik. ADSH, Bosch and EUSG's sponsors are substantially participating in the PIPE. ADSH is 100% owned by the family of the CEO and his family's charitable foundation; the CEO has a majority of the votes in ADSH. A substantial portion of the funds from the transaction will be used to accelerate the development of ADS-TEC Energy's charging platforms and expand the company's reach into the United States and Europe. The boards of directors of both ADS-TEC Energy and EUSG have unanimously approved the transaction, which is expected to be completed in Q4. Completion of the proposed transaction is subject to, among other things, the approval of the shareholders of EUSG, satisfaction of the conditions stated in the definitive agreement and other customary closing conditions.

06:07 EDT Second Sight receives new $156K NIH grant supplement for Orion study - Second Sight received a grant supplement from the National Institutes of Health to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses. The study will help the company better understand acceptable risks, necessary benefits, and appropriate risk/benefit balance for visual cortical prostheses, from the perspective of the target population. The entirety of the $155,964 grant supplement will be provided to UCLA as a subcontractor to conduct the study. The grant supplement is related to the $6.4M NIH grant for the Early Feasibility Clinical Trial of a Visual Cortical Prosthesis. Second Sight reported promising two-year data from the Orion trial on May 12.

05:47 EDT Hyzon Motors signs 30-day trial agreement with TTSI for electric truck - Hyzon announced the signing of a trial agreement with Total Transport Services, or TTSI, a port trucking company in Southern California and a provider of logistics services with expertise in distributing imports within the U.S. and Canada. Under the agreement, Hyzon will provide a Class 8 heavy-duty fuel cell electric truck to TTSI for a 30-day trial in Q4. The truck, built on a 2022 Freightliner Cascadia chassis, is expected to have 600 peak horsepower and a range of up to 400 miles. Because of those specifications, the truck can be placed into TTSI's existing operations, hauling up to 82,000 pounds of gross combined vehicle weight, a standard load for TTSI, and taking advantage of the public heavy-duty hydrogen refueling station in Wilmington, California, nearby TTSI's Long Beach Custom's House operations. The trial will mark TTSI's first experience with a zero-emissions vehicle capable of 400 miles range.

05:11 EDT Manchester United enters partnership with Ecolab ahead of welcoming back crowds - Manchester United (MANU) has entered a partnership with Ecolab (ECL) to adopt its solutions across Old Trafford and the Carrington training ground. Manchester United will draw on Ecolab's expertise to create a cleaner environment for fans and promote public health as Old Trafford prepares to open the turnstiles to its largest crowds for 17 months. All areas of United's Old Trafford stadium and Carrington training ground are being equipped with Ecolab hand disinfectant, also used across the National Health Service. A customized textile care solution for United's laundry will deliver improved safety, and sustainability when washing kits and linens; and the Club's groundskeeping team will be advised on how to optimize the quality of water used to irrigate pitches. To maximize the benefits of the partnership, Ecolab has designated an in-house expert to advise Manchester United and oversee implementation of the new solutions and technology across the Club.